DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
We've - 1 Bill Sutherland - 1 Piper Sandler - 1 Matt O'Brien - 1 Stryker - 1 Eli Lilly's Mounjaro - 1 O'Brien - 1 Richard Newitter - 1
Top related locs:
U.S GLP
Top related orgs:
American College of - 1 Nordisk's Ozempic - 1 Stryker - 1 Surgery Partners - 1 Permanente - 1 Tenet Healthcare - 1 Partners - 1

Search resuls for: "Richard Newitter"


2 mentions found


☆ Many are betting Ozempic will reduce the need for knee surgery. What it means if they're wrong
  + stars: | 2023-10-14 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +5 min
Medical device stocks of all kinds were pummeled over the past week as investors tried to calculate the ripple effects of new weight loss drugs. While the use of the GLP-1 drugs to treat obesity is still very limited at this point, it is expected to soar to a $100 billion market or more, by some estimates. Judging by the momentum in the stocks, investors have been betting that as people lose weight, there will be a decline in knee replacement surgery. A case for more knee surgery? Based on Truist's polling of 50 hospital administrators, the analyst expects the third quarter will show a slowing pace of knee replacement surgeries compared to the first half of 2023.
Persons: We've, Bill Sutherland, Piper Sandler, Matt O'Brien, Stryker, Eli Lilly's Mounjaro, O'Brien, Richard Newitter, Newitter, Benchmark's Sutherland, Kaiser, Sutherland, — CNBC's Michael Bloom Organizations: American College of, Nordisk's Ozempic, Stryker, Surgery Partners, Permanente, Tenet Healthcare, Partners Locations: U.S, GLP
☆ TipRanks reveals the top 10 health care sector analysts of the past decade
  + stars: | 2023-05-21 | by ( Tipranks.Com Staff | ) www.cnbc.com   time to read: +5 min
TipRanks leveraged its Experts Center tool to recognize the ones with a high success rate. We also analyzed each stock recommendation made by health care sector analysts in the past decade. TipRanks' algorithms calculated the statistical significance of each rating, average return and the analysts' overall success rate. The buy recommendation generated a return of 397.9% from May 12, 2020 to May 12, 2021. Boris Peaker - TD CowenBoris Peaker has the 10th spot on the list, with a success rate of 47%.
0 next >>
Total: 2